
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is well positioned by seralutinib, whose late September NDA submission for PAH is supported by PROSERA and TORREY data, including a +13.3 m placebo-adjusted 6MWD benefit and a safety profile viewed as manageable in a high-unmet-need disease. The FDA has framed the statistical significance and effect size as a review issue rather than a filing barrier, while the company expects a standard review and is preparing for commercialization within ~one-year after re-acquiring worldwide rights in July 2026. Financially, Gossamer Bio ended 3Q26 with $51.2M in cash, and milestone-linked financing could add $125M upon NDA acceptance and $100M upon approval, while management still sees $2B+ peak sales potential worldwide.
Bears say
Gossamer Bio is viewed negatively because seralutinib, the main value driver, faces substantial regulatory risk after PROSERA missed its prespecified primary endpoint, leaving FDA free to demand another controlled study, issue a Complete Response Letter, or approve only a narrower label. The efficacy package is also vulnerable, as the +13.3 m placebo-adjusted 6MWD gain in the ITT population is modest, the subgroup strength may be seen as too narrow, and safety concerns persist with discontinuations at 15.0% versus 5.8% and adverse events of special interest at 20.5% versus 6.3%. Even if approved, commercial execution is uncertain in an increasingly competitive PAH market where it would likely be a third or later agent, while Chiesi’s exit leaves Gossamer responsible for development, launch, and potentially dilutive financing needs.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Gossamer Bio Inc (GOSS) Forecast
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares